Home
BIO
BIO News

Latest Bio-Rad Laboratories Inc. (BIO) News on July 1, 2025

Argus Research

6 days ago

BIO: Raising target price to $190.00

Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?

Zacks

15 days ago

Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?

Argus Research

20 days ago

BIO: Raising target price to $242.00

Bio-Rad’s Management to Host Investor Meetings During Jefferies Global Healthcare Conference

Business Wire

a month ago

Bio-Rad’s Management to Host Investor Meetings During Jefferies Global Healthcare Conference

Argus Research

a month ago

BIO: Lowering target price to $259.00

Argus Research

2 months ago

BIO: Raising target price to $266.00

Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends

Zacks

2 months ago

Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

Business Wire

2 months ago

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

Bio-Rad Laboratories First Quarter 2025 Earnings: EPS: US$2.29 (vs US$13.46 in 1Q 2024)

Simply Wall St.

2 months ago

Bio-Rad Laboratories First Quarter 2025 Earnings: EPS: US$2.29 (vs US$13.46 in 1Q 2024)

Argus Research

2 months ago

BIO: Rating increased to a HOLD

Analysts Have Been Trimming Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target After Its Latest Report

Simply Wall St.

2 months ago

Analysts Have Been Trimming Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target After Its Latest Report

Morningstar Research

2 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

Morningstar Research

2 months ago

Analyst Report: Bio-Rad Laboratories, Inc.

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Bio Rad Laboratories Inc Earnings Call

MT Newswires

2 months ago

UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating

BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

Zacks

2 months ago

BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

MT Newswires

2 months ago

RBC Cuts Price Target on Bio-Rad Laboratories to $392 From $409, Keeps Outperform Rating

MT Newswires

2 months ago

Bio-Rad Laboratories Q1 Adjusted Earnings Rise, Revenue Falls

Bio-Rad Laboratories Inc (BIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

GuruFocus.com

2 months ago

Bio-Rad Laboratories Inc (BIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Associated Press Finance

2 months ago

Bio-Rad: Q1 Earnings Snapshot

Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Zacks

2 months ago

Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Bio-Rad Reports First-Quarter 2025 Financial Results

Business Wire

2 months ago

Bio-Rad Reports First-Quarter 2025 Financial Results

Bio-Rad Laboratories, Inc. (BIO): Among Billionaire Mason Hawkins’ Small-Cap Stocks with Huge Upside Potential

Insider Monkey

2 months ago

Bio-Rad Laboratories, Inc. (BIO): Among Billionaire Mason Hawkins’ Small-Cap Stocks with Huge Upside Potential

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Zacks

2 months ago

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

GlobeNewswire

2 months ago

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Argus Research

2 months ago

BIO: What does Argus have to say about BIO?

Insider Monkey

2 months ago

Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile?

Should You be Optimistic on Bio-Rad Laboratories’s (BIO) Outlook?

Insider Monkey

2 months ago

Should You be Optimistic on Bio-Rad Laboratories’s (BIO) Outlook?

Argus Research

3 months ago

BIO: Raising target price to $196.00

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Business Wire

3 months ago

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Morningstar Research

3 months ago

Analyst Report: Bio-Rad Laboratories, Inc.

Argus Research

3 months ago

BIO: Lowering target price to $176.00

MT Newswires

3 months ago

RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating

Morningstar Research

3 months ago

Analyst Report: Bio-Rad Laboratories, Inc.

Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61%

Simply Wall St.

3 months ago

Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61%

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

Zacks

3 months ago

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

Argus Research

3 months ago

BIO: Lowering target price to $192.00

Bio-Techne Opens New Customer Experience Centre in Germany

Zacks

3 months ago

Bio-Techne Opens New Customer Experience Centre in Germany

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate

Zacks

3 months ago

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate

Argus Research

3 months ago

BIO: Rating decreased to a SELL

Alger Russell Innovation Index Updates for First Quarter 2025

PR Newswire

3 months ago

Alger Russell Innovation Index Updates for First Quarter 2025

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%

Simply Wall St.

4 months ago

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%

Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?

Insider Monkey

4 months ago

Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?

Argus Research

4 months ago

BIO: Lowering target price to $263.00

Bio-Rad (BIO) International Revenue Performance Explored

Zacks

4 months ago

Bio-Rad (BIO) International Revenue Performance Explored

Argus Research

4 months ago

BIO: Lowering target price to $291.00

HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

Zacks

4 months ago

HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

Zacks

4 months ago

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

Zacks

4 months ago

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Zacks

4 months ago

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Zacks

4 months ago

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Argus Research

4 months ago

BIO: Rating increased to a HOLD

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

Zacks

4 months ago

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

BIO Stock Might Rise Following the Offer to Acquire Stilla

Zacks

4 months ago

BIO Stock Might Rise Following the Offer to Acquire Stilla

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks

4 months ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Bio-Rad price target lowered to $447 from $477 at RBC Capital

TipRanks

5 months ago

Bio-Rad price target lowered to $447 from $477 at RBC Capital

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

5 months ago

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Morningstar Research

5 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Zacks

5 months ago

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad set to acquire Stilla Technologies

Medical Device Network

5 months ago

Bio-Rad set to acquire Stilla Technologies

Morningstar Research

5 months ago

Analyst Report: Bio-Rad Laboratories, Inc.

MT Newswires

5 months ago

UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating

MT Newswires

5 months ago

RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating

Thomson Reuters StreetEvents

5 months ago

Q4 2024 Bio Rad Laboratories Inc Earnings Call

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

Zacks

5 months ago

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

GuruFocus.com

5 months ago

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Zacks

5 months ago

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Associated Press Finance

5 months ago

Bio-Rad: Q4 Earnings Snapshot

MT Newswires

5 months ago

Bio-Rad Laboratories' Q4 Adjusted Earnings, Revenue Fall

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Zacks

5 months ago

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Report Preview: What To Look For

GuruFocus.com

5 months ago

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Report Preview: What To Look For

OncoCyte prices $29.1M equity offering

TipRanks

5 months ago

OncoCyte prices $29.1M equity offering

Oncocyte Prices $29.1 Million Equity Offering

GlobeNewswire

5 months ago

Oncocyte Prices $29.1 Million Equity Offering

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

Zacks

5 months ago

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

Zacks

5 months ago

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

Zacks

5 months ago

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Zacks

5 months ago

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance

Zacks

5 months ago

Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance

Argus Research

5 months ago

BIO: Lowering target price to $279.00

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Zacks

5 months ago

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

MT Newswires

5 months ago

RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating

Argus Research

5 months ago

BIO: Raising target price to $294.00

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Insider Monkey

5 months ago

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Business Wire

5 months ago

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Argus Research

5 months ago

BIO: Lowering target price to $283.00

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Zacks

5 months ago

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now

Zacks

5 months ago

Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now

Argus Research

6 months ago

BIO: Raising target price to $294.00

MT Newswires

6 months ago

Bio-Rad Laboratories Led $105 Million Series C Funding Round for Geneoscopy

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Business Wire

6 months ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Business Wire

6 months ago

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Simply Wall St.

6 months ago

At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Argus Research

6 months ago

BIO: Rating increased to a HOLD

Argus Research

6 months ago

BIO: Lowering target price to $277.00

Argus Research

7 months ago

BIO: Lowering target price to $278.00

MT Newswires

7 months ago

RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating

Argus Research

7 months ago

BIO: Raising target price to $291.00

Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?

Zacks

7 months ago

Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Simply Wall St.

7 months ago

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory

Insider Monkey

7 months ago

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory

Share on Social Networks: